BSX Boston Scientific Corporation

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

BSX's MedSurg segment supports growth, with Endoscopy and Neuromodulation gains offsetting Urology challenges and portfolio gaps.

Boston Scientific (BSX) stock has lost more than half its value over the past 12 months, while the S&P 500 returned 18.0%. A subsequent setback occurred in September, when the company said a cyberattack would likely keep it from meeting its guidance. If the wider market turns now, how big could the next fall be, and how long would you wait? The answer depends on how well Boston Scientific is equipped to absorb a broader downturn today.

Wells Fargo has put a number on the damage Boston Scientific Corporation’s (NYSE:BSX) August cybersecurity incident could do to its third-quarter results, which comes up to roughly $300 million in sales and about $0.13 per share in earnings. Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Boston Scientific to $48 from $50 […]

Oppenheimer has become considerably more cautious on Boston Scientific Corporation (NYSE:BSX), but not cautious enough to abandon its bullish rating. Analyst Suraj Kalia lowered the firm’s price target on Boston Scientific to $65 from $85 on September 21, ahead of the company’s quarterly results, while maintaining an Outperform rating. Kalia is also reducing Oppenheimer’s fiscal […]

Boston Scientific (BSX) is in focus after initiating a Class II recall of its StoneSmart Connect Console power adapters, affecting 982 units distributed across the US and multiple international markets. Against this recall backdrop, Boston Scientific’s share price has eased 1.7% over the last trading day and is down 6.2% over the past month, while the 1‑year total shareholder return has declined 54.7%, signaling fading momentum despite a small 2.9% gain on a 90‑day share price basis. Scan how...

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Boston Scientific (NYSE: BSX) has started a voluntary global recall of its StoneSmart Connect Console over a power adapter safety issue. The company is informing hospitals and healthcare providers worldwide about the recall and advising on identification and return of affected units. Arthur C. Butcher, who oversees key endoscopy and urology portfolios, has notified Boston Scientific of his decision to retire. The recall of StoneSmart Connect and Arthur C. Butcher's retirement only capture...

In the closing of the recent trading day, Boston Scientific (BSX) stood at $44.92, denoting a +2.74% move from the preceding trading day.

Boston Scientific (BSX) stock has fallen 55.5% over the past twelve months, and at $43.72 it trades barely above its 52-week low of $42.63. The options market now prices a likely one-year range from $28.46 to $67.16 a share. That band is wide, but it is close to how much the stock has already been moving.

The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

BSX's upcoming launches, from SEISMIQ 4CE to FARAFLEX, are likely to provide new growth opportunities across key businesses.

AGCO, AEG and BSX have been added to the Zacks Rank #5 (Strong Sell) List on September 21st, 2026.

After decades of spinoffs and separations of various parts, GE Aerospace is now trending toward integration.

Boston Scientific has seen its share price fall sharply over the past year, which naturally raises a question for investors who care about fundamentals. Are the cash flows that the business can generate enough to support where the stock trades today, or has sentiment moved further than the underlying economics justify? The share price has declined 55.4% over the past year, so the recent slide puts the focus squarely on whether that move lines up with the cash that Boston Scientific can...

Boston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.

Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls

Lyft downgraded, Trip.com upgraded: Wall Street's top analyst calls

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.

Boston Scientific (NYSE:BSX) has initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and software over atrial fibrillation Burden Alert delays. The recall targets multiple versions of LUX-Dx hardware and associated software that may postpone detection alerts for atrial arrhythmias used in patient monitoring. The US FDA has taken enforcement interest in the action, underscoring regulatory scrutiny of the cardiac monitoring platform and its alert...

An analysis of recent filings from American politicians shows that Accenture (NYSE: ACN) and Boston Scientific (NYSE: BSX) saw an uptick in purchases from notable politicians. Rep. Gilbert Ray Cisneros, Jr. (D-CA) bought Boston Scientific shares, according to a filing earlier this month. The trade was made on August 18, 2026. Rep. Ro Khanna (D-CA) […]

The decision is part of J&J’s strategy to prioritize resources for the greatest impact and positions Laminar for success under dedicated ownership, a spokesperson said.

AGCO, BSX and BBWI have been added to the Zacks Rank #5 (Strong Sell) List on September 16th, 2026.

Boston Scientific (BSX) stock has fallen about 57% over the past year, to about $45. The shares now sell for 3.2 times trailing sales, hovering near their decade-long historical trough of roughly 3.0 times and well off their 8.6 high.

Looking back on medical devices & supplies - diversified stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Boston Scientific (NYSE:BSX) and its peers.

A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.

BSX's deal-making push expands its reach into high-growth markets, with Penumbra adding a major thrombectomy opportunity.

Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Though operations have since resumed, the incident […]

Boston Scientific (BSX) trades at about $43, roughly 17% below the recent high it set on 19th Aug, 2026. Its own history with sharp drops is encouraging. That history does not cover a cyberattack it says is likely to hit its 2026 results, and the stock is down about 60% over the past twelve months. Start with the history.

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

CEO Mike Mahoney gave more details at a Thursday investor conference, saying the company likely lost orders while its plants and distribution centers were shut down.

Boston Scientific (BSX) reached $43.1 at the closing of the latest trading day, reflecting a -4.14% change compared to its last close.

The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 25.7% over the past six months while the S&P 500 was up 13.6%.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

(Updates with market moves at the end of the day, and other changes, if any.) US stocks fell for

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th

(Updates with latest market prices and developments.) US benchmark equity indexes were lower intr

Boston Scientific (BSX) flagged its inability to meet its near-term financial outlooks amid a "mater

The medical device maker said it is unlikely to meet its full-year sales growth and adjusted earnings targets, and will update investors on Oct. 28

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St

Boston Scientific expects to provide updated full-year 2026 guidance along with its third-quarter results on Oct. 28, 2026.

All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve

Medical-device maker Boston Scientific said that it is unlikely to meet its sales growth and earnings expectations for the year, citing a major cyberattack disclosed last month that left it unable to fill orders.

On this episode of Stock Movers: - Novartis (NOVN) shares are lower as it suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting disease failed a late-stage study. - Boston Scientific (BSX) shares are moving on news it said that fallout from a cybersecurity incident has impacted its ability to ship its products to customers and will cause the medical devices company to miss its sales growth and earnings estimates for the year. - Intel (INTC) is rising on a report that the company could raise computer chip prices next month.

Boston Scientific said Tuesday a cybersecurity incident is likely to have a material impact on its third-quarter and full-year results.